D-0832-2022 Class II Terminated

Recalled by Macleods Pharma Usa Inc — Plainsboro, NJ

FDA drug recall D-0832-2022 was initiated by Macleods Pharma Usa Inc on Apr 15, 2022 and is designated Class II. Reason for recall: CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits The recall status is terminated (terminated Oct 13, 2023). Affected quantity: 12,408/90 count bottles; 1670/1000 count bottles =2,786,720 tablets.

Recall details

Product Type
Drugs
Report Date
May 11, 2022
Initiation Date
Apr 15, 2022
Termination Date
Oct 13, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
12,408/90 count bottles; 1670/1000 count bottles =2,786,720 tablets

Product description

Losartan Potassium Tablets, USP, 25 mg, a) 90-count bottles (NDC # 33342-044-10), b) 1000-count bottles (NDC # 33342-044-44), Rx Only, MFR: Macleods Pharma USA, Inc. Plainsboro, NJ 08536

Reason for recall

CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits

Distribution pattern

Product was distributed nationwide.

Code information

Lot # BLH2002A, exp. date 11/2022 BLH2003B, exp. date 11/2022 BLH2004A, exp. date 11/2022

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0832-2022
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0832-2022. Report a data issue: hello@regdatalab.com.